Do You Need a Japan Marketing Authorization Holder Licence to Sell Cosmetics or Quasi-Drugs?

Most overseas beauty brands meet Japanese pharmaceutical regulation from the wrong end. They find the advertising rules first — which claims a moisturiser may make, which words a serum may not use — because that is where the visible problems are, and it is what our guide to Japanese advertising compliance covers. But an earlier gate decides whether the product may reach a Japanese shelf at all, however carefully the copy is written: the marketing authorization licence.

One boundary before anything else. LAUNOVA operates Japanese storefronts and marketplace accounts for overseas brands. We do not hold a cosmetics or quasi-drug marketing authorization licence, we do not act as anyone's marketing authorization holder, and we do not offer licence-holding or pharmaceutical-affairs representation as a service. If your product needs that role filled, it needs a licensed Japanese marketing authorization holder or a specialist pharmaceutical-affairs consultancy — not us. What follows is a decision framework built from the statute and from prefectural regulators' own published material, so that you can walk into that conversation knowing what you are buying.

What the Licence Actually Gates

The regulated activity is narrower and stranger than most brands expect. Article 12(1) of the Act says that no person may, as a business, carry out the manufacture and sale (製造販売) of pharmaceuticals, quasi-drugs or cosmetics without the corresponding licence — a quasi-drug marketing authorization licence for quasi-drugs, a cosmetics marketing authorization licence for cosmetics.

The trap is the phrase 製造販売 itself. It means neither "manufacturing" in the factory sense nor "retailing": it means being the party that releases the product into the Japanese market — the entity that takes finished goods, however sourced, and puts them into Japanese distribution under its own responsibility. Importing finished cosmetics and shipping them onward to a Japanese retailer or marketplace is squarely inside that definition — and it is worth separating this regulatory question from the commercial one of who bears the loss if that same shipment is damaged or lost before it clears customs, which our guide to cargo insurance for Japan imports covers. Japan Customs states the consequence in one line: cosmetics, quasi-drugs and medical devices may not be imported as a business by anyone without the marketing authorization licence.

That is also why the licence cannot be deferred until sales justify it: it is a condition of the first commercial import, not a threshold that kicks in at some revenue level. Article 84(2) puts violation of Article 12(1) at up to three years' imprisonment or a fine of up to ¥3 million, or both.

The one route that genuinely avoids it

There is a real carve-out, and it is worth stating precisely because brands often mis-scope it. An individual importing for their own use does not need the licence. Japan Customs publishes the quantities that clear without an import confirmation certificate: for cosmetics, up to 24 items per product in standard size; for external-use quasi-drugs, also 24 items; for other quasi-drugs, up to a two-month supply by dosage.

That is the legal basis for the cross-border personal-import model, and for some brands it is a sensible first test of Japanese demand. What it cannot do is scale into local inventory: the moment you want stock in a Japanese warehouse, marketplace fulfilment, or a domestic-shipping storefront, you are importing as a business and the licence is back in play. Treat it as a channel with a hard ceiling, not a permanent structure.

Why Your Overseas Company Cannot Hold It

The statute never says "foreign companies are excluded." It does something more effective: it locates the licence geographically. Article 80(2) of the Enforcement Order assigns the licensing power to the governor of the prefecture in which the office of your General Marketing Compliance Officer (総括製造販売責任者) carries out that officer's work. There is no national licence and no route for an applicant with no Japanese office — the application has to name a prefecture, and it names it via a physical office where a specific named person works.

Tokyo's published checklist shows what that means in documents. A corporate applicant must attach a certificate of registered matters (登記事項証明書) issued within the previous six months — proof of a company registered in Japan — plus the compliance officer's employment contract, with days off stated concretely enough to verify a genuine working pattern (Tokyo explicitly rejects vague formulations like "days designated by the company"), an organisation chart, floor plans showing where the compliance officer sits, and documented quality-management (GQP) and post-marketing-safety (GVP) structures.

The compliance officer is not a nominal title either, and the bar is not the same for both licences. For a cosmetics licence, Article 85-2(2) of the Enforcement Regulations accepts a licensed pharmacist; or someone who completed a specialist course in pharmacy or chemistry at upper-secondary level or above; or someone who studied pharmacy or chemistry subjects at that level and then worked at least three years in quality control or post-marketing safety management of pharmaceuticals, quasi-drugs or cosmetics; or a person the Minister recognises as equivalently qualified. For a quasi-drug licence, Article 85-2(1) sets a higher bar: the specialist-course route requires a university or college of technology rather than upper-secondary level, and the three-year experience route counts only work on pharmaceuticals or quasi-drugs — cosmetics experience does not qualify. Article 17(2) of the Act adds that the officer must have the ability and experience to actually perform the role, and Article 17(3) gives them a statutory duty to state their opinion in writing to the company when necessary to keep quality and safety management proper — a person your organisation is legally required to let overrule commercial pressure.

Add these together and "can we hold it ourselves" resolves into an ordinary corporate-structuring question: are you prepared to incorporate in Japan, take an office, and employ a qualified pharmaceutical-affairs professional? For a brand already planning a Japanese subsidiary that is a manageable extra workstream; for a brand testing the market it is usually disproportionate — which is why the second route exists.

Cosmetics and Quasi-Drugs Are Two Different Gates

A point that trips up brands whose range spans both: these are separate licences with separate product-level regimes, not tiers of one licence. Japan decides whether a product is a cosmetic or a quasi-drug by its ingredients and claimed effects, not by how it is marketed at home — a whitening essence or an anti-acne treatment sold as ordinary skincare elsewhere may land on the quasi-drug side here.

The licence side is nearly symmetrical. The product side is not:

• Cosmetics: notification. A cosmetic that complies with the Cosmetics Standard and carries full ingredient labelling needs no per-item approval. Instead, Article 14-9(1) requires the marketing authorization holder to notify each item in advance, with changes notified within 30 days. Foreign manufacturer details are notified alongside. This is an administrative filing, not a review — the time cost is in preparing accurate ingredient and labelling data, not in waiting for an examiner.
• Quasi-drugs: approval. Article 14(1) requires per-item approval from the Minister of Health, Labour and Welfare for quasi-drugs (the article carves out quasi-drug classes the Minister designates by standard, so confirm your specific product rather than assuming the general rule). Article 14(2)(i) adds a sequencing rule that catches people out: approval is refused outright if the applicant does not already hold the corresponding Article 12(1) licence. You cannot run the two in parallel and hope they land together — the licence comes first, then the product approval. Tokyo's guidance notes that a defined list of quasi-drug categories (including hair dyes, permanent-wave agents, medicated toothpastes, bath additives and sanitary products, per a 1994 notification of the then Ministry of Health and Welfare) is approved at prefectural-governor level, while anything outside that list is handled through the national route.

Both categories share the same GQP and GVP officer structure, even though, as above, the compliance officer's own qualification bar is higher on the quasi-drug side. The GQP Ordinance treats quasi-drugs and cosmetics together in one chapter and requires each to appoint a quality assurance officer (品質保証責任者) who is not part of the sales function. The GVP Ordinance classes quasi-drug and cosmetics marketing authorization holders alike as Type 3 businesses, the lightest post-marketing safety regime, requiring a safety management officer under a simplified set of duties. If you read elsewhere that quasi-drugs demand a heavier officer structure than cosmetics, check it against the ordinances — the meaningful divergence is the approval-versus-notification gate, not the staffing.

The Partner Route — and What You Hand Over

The common structure for a brand without a Japanese entity is straightforward: a Japanese company that already holds the relevant licence acts as your marketing authorization holder, imports the goods, files the notifications or approvals, and releases the product into the market. In the cosmetics import trade these firms usually market themselves as 化粧品輸入代行 — cosmetics import agents — and the licence is the core of what they sell. It sits alongside the rest of a cross-border operation into Japan rather than replacing any of it.

Three consequences are structural rather than negotiable line items, and worth understanding before you sign.

Their name goes on your packaging. Article 61(1) requires the name and address of the marketing authorization holder on the immediate container or wrapper of every cosmetic; Article 59(1) does the same for quasi-drugs, which additionally must carry the words 医薬部外品. This is a statutory labelling item. A Japanese customer holding your product reads your partner's company name as the party responsible for it. Brands routinely discover this at artwork stage, months after the commercial terms were agreed.

They hold the filing, not you. Article 14-9(1) puts the notification duty on the marketing authorization holder. For ordinary cosmetics, that means the per-item notification exists in your partner's name. Switching partners is not a transfer of paperwork; it means the new licence holder files afresh, and your product's regulatory continuity in Japan depends on a relationship you do not control. Price that switching cost into the contract at the start — a partner who knows you cannot easily leave is negotiating from a different position at renewal than one who knows you can.

They carry the legal responsibility, which means they get a veto. The GQP Ordinance requires the quality assurance officer to confirm and record that each product was properly manufactured before market release, and to run recalls where needed. A licence holder who declines to release your batch is doing the job the statute assigns them, not being obstructive. Choosing a partner is therefore choosing whose quality judgement governs your Japanese supply chain — and a partner picked purely on price is one whose review process you have not examined.

What agents publish for this work

Published rates are scarce, but two Japanese import agents do post figures that give a usable order of magnitude. Both are the vendors' own published price lists — not independently audited, and not a LAUNOVA quote.

YUNIGE (Osaka) publishes: ingredient and claim screening at ¥3,000 per item (first time, before tax); filing of the foreign-manufacturer notification and the cosmetics marketing notification at ¥3,000 per manufacturer plus ¥1,500 per item; Japanese label design at ¥3,000 per item; an import agency fee of 3% of invoice value; and statutory-label application at ¥10–50 per label. A second agent, trading as 化粧品輸入代行.jp, publishes a floor of ¥42,000 for a package covering the legal filings, ingredient-compliance screening and laboratory testing, itemised as ¥10,000 per product for prohibited-ingredient screening, ¥10,000 plus ¥7,000 for analysis handling and formalin testing, ¥15,000 per product for the regulatory filing, and ¥30,000 per shipment or 3% of FOB for customs handling. That second page carries an undated COVID-era promotional banner, so treat its figures as possibly stale and confirm before relying on them.

These numbers show the shape of the cost, not the total. Per-item filing is cheap — tens of thousands of yen, not millions. What actually moves a Japan launch budget is the percentage fee on import value and the per-unit labelling work, both of which scale with volume. Get quotes from at least two agents and compare the percentage terms, not the filing fees.

The Quasi-Drug Exception That Changes the Answer

Here is the provision that rarely appears in English-language guidance, and it materially changes the calculation for anyone selling quasi-drugs.

Article 19-2(1) allows a foreign manufacturer to apply directly to the Minister of Health, Labour and Welfare for approval of a product intended for export to Japan — and to hold that approval in its own name. Under Article 19-2(3), the foreign applicant must appoint a Japanese licensed marketing authorization holder at the time of application, to take the measures needed inside Japan to prevent public-health harm. Article 19-2(4) then lets that designated marketing authorization holder (選任製造販売業者) place the product on the market notwithstanding the ordinary Article 14(1) rule.

The commercial consequence is the important part. Under this structure the regulatory asset stays with the brand. Article 19-3(1) requires only that the foreign approval holder notify the Minister within 30 days when it changes its designated Japanese partner. Changing partners becomes a notification, not a refiling — the opposite of the ordinary cosmetics-notification position described above.

Two limits, stated plainly. First, this route runs through Article 14(1), so it is available only for products that require approval: quasi-drugs, and the narrow class of cosmetics containing MHLW-designated ingredients. An ordinary cosmetic that only needs an Article 14-9 notification has no equivalent route — the notification is the licence holder's, full stop. Second, the appointed Japanese company must itself hold the marketing authorization licence for the relevant product type, so this does not remove the need for a Japanese partner; it changes who owns the approval behind them.

If your Japanese range spans both categories, design around this asymmetry deliberately rather than discovering it later — and ask a prospective partner to explain the Article 19-2 structure unprompted. If they cannot, that is itself a data point.

One More Licence People Forget: Packaging and Labelling

Japanese statutory labelling has to physically exist on the product before it reaches a customer. Article 61 lists what a cosmetic's immediate container must show: the marketing authorization holder's name and address, the product name, the manufacturing number or code, designated ingredients, an expiry date where designated, and the items required by any applicable standard. In practice that means a Japanese-language label.

Where that label is applied determines whether you need a second licence. If the labelling and packaging happen inside Japan, that is a manufacturing step, and Article 13(1) requires a manufacturing licence for the site. Enforcement Regulation Article 25(3) provides a limited category — packaging, labelling and storage only — for exactly this case, distinct from the general manufacturing category. Tokyo prices it at ¥32,800 for a new licence and ¥23,600 on renewal, against ¥39,000 and ¥25,600 for the general category, with the same 35-business-day standard processing period.

Brands using an import agent rarely see this separately, because the agent holds the packaging licence and folds label application into the per-unit fee above. It matters if you are considering doing it yourself, or when a third-party logistics provider offers to apply your Japanese labels — a 3PL without this licence cannot legally do that work, which is worth asking before signing a warehousing contract. The operational plan and the regulatory plan have to be built against each other, because a warehouse decision can create a licensing requirement nobody budgeted for.

A Decision Rule, in Order

Four questions, answered in sequence, settle the structure faster than a cost comparison:

1. Are you importing as a business, or is this genuinely personal import? If Japanese customers buy from your overseas site and import parcels themselves within the published personal-use quantities, no licence is engaged and no further question applies. If you want local stock, marketplace fulfilment or domestic shipping, you are importing as a business and everything below is live.
2. Is your range cosmetics, quasi-drugs, or both? Get this classified by ingredient and claimed effect before anything else, because it determines whether you face per-item notification or per-item approval, and whether the Article 19-2 route is even available to you. Classification is a specialist judgement, not a reading of your existing marketing copy.
3. Are you incorporating in Japan anyway? If a Japanese entity is already in the plan for other reasons, holding the licence yourself is an incremental workstream — government fees in the tens of thousands of yen and roughly 35 business days of processing, on top of an office and a qualified compliance officer. If a Japanese entity is not in the plan, the licence alone rarely justifies creating one.
4. If a partner holds it, what have you priced for exit? For ordinary cosmetics, assume the notification stays with them and refiling is the cost of leaving. For quasi-drugs, ask specifically whether the Article 19-2 structure can put the approval in your name — if it can, the same partner change becomes a 30-day notification instead.

A pattern we repeatedly meet in market-entry conversations is a brand that answers question three too late. Regulatory structure gets treated as a compliance chore to be delegated after the commercial plan is fixed, when in fact it determines who owns the product's Japanese identity, whose name is on the pack, and how expensive it is to change your mind in year two. Deciding early costs a few weeks of specialist advice; deciding late can mean rebuilding artwork, refiling notifications and renegotiating from weakness.

Where we fit is deliberately narrow. We do not hold the licence, act as a marketing authorization holder, or give pharmaceutical-affairs advice — that work belongs to a licensed Japanese marketing authorization holder or a specialist consultancy, and we will say so rather than stretch our scope. What we do is run the Japanese storefront and marketplace operations the products land in once the regulatory structure is settled, and help sequence the launch so that the warehousing, labelling and platform decisions do not quietly create regulatory problems. If that is the gap on your side, tell us where your Japan plan stands today. Scope and pricing are quoted against the work rather than published as a rate card.